Our Pricing

Wegovy Weight Loss Injections UK: Clinical Evidence and Access

If you're searching for wegovy weight loss injections uk, you'll find transparent pricing and expert clinical support at Cured Pharmacy. As a GPhC-registered pharmacy (9012511), we supply genuine UK-licensed Wegovy pens from £79.00, with every prescription reviewed by our UK clinical team including superintendent pharmacist Tarun Kumar (GPhC 2233073).

How Wegovy Weight Loss Injections Work in Clinical Practice

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics the natural GLP-1 hormone, which regulates appetite through the hypothalamus and slows gastric emptying, creating sustained feelings of fullness after smaller meals.

In the landmark STEP 1 trial involving 1,961 participants, patients receiving once-weekly semaglutide 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Approximately two-thirds of participants on Wegovy lost at least 10% of their initial body weight, and nearly one-third lost 20% or more.

The medication works progressively through a structured dose escalation schedule, starting at 0.25mg weekly and increasing gradually over 16-20 weeks to the maintenance dose of 2.4mg. This titration minimises gastrointestinal side effects whilst allowing your body to adapt to the medication's appetite-suppressing effects [2].

Wegovy Dosing Schedule and Administration Guidance

Each Wegovy pen is a pre-filled, single-dose injection administered subcutaneously once weekly, typically in the abdomen, thigh, or upper arm. The injection process takes less than a minute, and most patients find the fine needle causes minimal discomfort.

The standard escalation follows this MHRA-approved schedule: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, and the maintenance dose of 2.4mg from week 17 onwards [2]. Your UK prescriber may adjust this timeline based on your tolerance and response.

Consistency matters significantly with GLP-1 therapy. Choose a specific day each week for your injection and maintain that schedule, as irregular dosing can reduce efficacy and increase side effects. If you miss a dose by more than five days, contact your prescriber before resuming treatment, as you may need to restart at a lower dose.

Storage and Handling Requirements

Store unused Wegovy pens in the refrigerator between 2°C and 8°C, away from the freezer compartment. Once you begin using a pen, it can be stored at room temperature (below 30°C) or in the refrigerator for up to 28 days. Always keep the pen cap on when not in use to protect from light, and never use a pen that has been frozen or exposed to direct sunlight.

Common Side Effects and Clinical Management Strategies

The most frequently reported side effects with Wegovy are gastrointestinal, including nausea (44% of patients in trials), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These effects typically emerge during dose escalation and diminish over 4-8 weeks as your body adapts.

Practical management strategies include eating smaller, more frequent meals rather than three large ones, avoiding high-fat and heavily spiced foods during the first month, staying well-hydrated throughout the day, and taking your injection after your evening meal rather than before breakfast. Many patients find that ginger tea or peppermint can ease mild nausea.

Serious adverse events are uncommon but require immediate medical attention. Contact your GP or NHS 111 if you experience severe abdominal pain that doesn't resolve (potential pancreatitis), persistent vomiting preventing fluid intake, visual changes, or signs of thyroid swelling. Wegovy carries a black box warning regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans [2].

When to Contact Your Prescriber

Reach out to your clinical team if side effects persist beyond eight weeks, you experience unexplained weight gain whilst on the maintenance dose, or you're unable to progress through the dose escalation schedule due to tolerability issues. Your prescriber may recommend staying at a lower dose for additional weeks or implementing dietary modifications before advancing.

Wegovy Eligibility Criteria and Assessment Process at Cured Pharmacy

Wegovy is licensed for adults with an initial BMI of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea [2]. The medication is not suitable for individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or previous serious hypersensitivity to semaglutide.

Our online consultation takes under three minutes and collects essential medical information including your current weight and height, previous weight management attempts, existing medical conditions, current medications, and any contraindications to GLP-1 therapy. A UK-registered prescriber reviews every assessment individually—there are no automated approvals.

If your consultation is approved, we'll dispense your prescription from our GPhC-registered premises and arrange discreet next-day delivery via tracked courier. Prices are transparent before you begin: Wegovy starts from £79.00 per month, with no hidden consultation fees or subscription charges added at checkout.

Long-Term Weight Maintenance and Lifestyle Integration

Clinical trials demonstrate that Wegovy is most effective when combined with a reduced-calorie diet and increased physical activity [1]. The medication creates a physiological environment conducive to weight loss by reducing hunger and food cravings, but sustainable results require behavioural changes alongside pharmacotherapy.

NICE guidance recommends aiming for a 5-10% weight reduction in the first six months of treatment, with ongoing monitoring every three months thereafter [3]. If you haven't achieved at least 5% weight loss after 12 weeks on the maintenance dose, your prescriber will reassess whether continuing treatment is appropriate.

Weight regain after discontinuation is common, with studies showing patients regain approximately two-thirds of lost weight within one year of stopping semaglutide [4]. This reflects the chronic nature of obesity as a disease and suggests that many patients may benefit from long-term therapy, subject to ongoing clinical review and tolerability.

Building Sustainable Habits

Focus on protein-rich foods to preserve lean muscle mass during weight loss, incorporate resistance training twice weekly alongside cardiovascular exercise, prioritise seven to nine hours of sleep nightly to optimise metabolic hormones, and work with a registered dietitian if possible to develop personalised nutrition strategies. Wegovy provides the physiological support, but lasting change requires addressing the environmental and behavioural factors that contributed to weight gain.

Comparing Wegovy to Alternative Weight Loss Treatments Available in the UK

Several prescription weight loss medications are licensed in the UK, each with distinct mechanisms, efficacy profiles, and administration requirements. Understanding these differences helps you and your prescriber select the most appropriate option for your circumstances.

Saxenda contains liraglutide, an earlier GLP-1 receptor agonist requiring daily injections rather than weekly. In the SCALE trial, liraglutide 3mg daily produced an average weight loss of 8% over 56 weeks [5]—effective, but lower than the 14.9% observed with Wegovy. The daily injection schedule may suit patients who prefer more frequent dosing adjustments or have concerns about longer-acting medications.

Orlistat is an oral lipase inhibitor that blocks approximately 30% of dietary fat absorption. It's available both on prescription and over-the-counter at lower doses, making it more accessible, but clinical trials show more modest weight loss averaging 3-5% [6]. Gastrointestinal side effects can be significant, particularly if dietary fat intake isn't carefully controlled. Orlistat may be appropriate for patients who cannot tolerate injectable therapies or have contraindications to GLP-1 medications.

Emerging Therapies and Future Options

Tirzepatide, a dual GIP/GLP-1 receptor agonist recently licensed in the UK, has demonstrated even greater weight loss than semaglutide in head-to-head trials, with average reductions of 20-22% at the highest doses [7]. As this medication becomes more widely available, it may offer an alternative for patients who don't achieve adequate results with Wegovy or prefer a different receptor mechanism. Your prescriber can discuss whether newer agents are suitable based on your individual response and clinical profile.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Novo Nordisk. (2023). Wegovy 2.4 mg Solution for Injection in Pre-filled Pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799
3. National Institute for Health and Care Excellence. (2023). Semaglutide for Managing Overweight and Obesity: Technology Appraisal Guidance [TA875]. https://www.nice.org.uk/guidance/ta875
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
5. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
6. Torgerson, J. S., et al. (2004). XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155
7. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed by the MHRA for chronic weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, and should be used alongside a reduced-calorie diet and increased physical activity.